Arbutus Biopharma (ABUS) Price & Analysis

Compare

1,254 Followers

ABUS Stock Chart & Stats

Day’s Range― - ―

52-Week Range$2.71 - $4.73

Previous CloseN/A

Volume149.14K

Average Volume (3M)811.23K

Market Cap

$732.29M

Enterprise Value$501.43M

Total Cash (Recent Filing)$98.09M

Total Debt (Recent Filing)$5.00M

Price to Earnings (P/E)―

Beta0.23

Next Earnings

Nov 05, 2025

EPS Estimate

-0.03

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.01

Shares Outstanding191,698,700

10 Day Avg. Volume1,145,709

30 Day Avg. Volume811,225

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.68

Enterprise Value/Revenue32.53

Enterprise Value/Gross Profit82.03

Enterprise Value/Ebitda-9.44

Forecast

1Y Price Target

$3.50

Price Target Upside-12.72% Downside

Rating ConsensusHold

Number of Analyst Covering0

Bulls Say, Bears Say

Bulls Say

Financial ManagementArbutus ended 2024 with $123M in cash and highlighted a 'continued focus on efficient deployment of financial resources and personnel.'

Legal ProceedingsA positive outcome to the Markman hearing was viewed as favorable for Arbutus.

Product DevelopmentAnalyst recommends a Buy rating, affirming confidence in the potential of imdusiran as a core component for achieving a functional cure in HBV.

Bears Say

Clinical TrialsArbutus has discontinued the planned IM-PROVE III Phase 2a trial of imdusiran plus anti-PD-L1 antibody durvalumab prior to initiation.

Legal ChallengesArbutus and partner Genevant expand their LNP legal activity against Moderna globally.

Restructuring CostsArbutus anticipates a one-time restructuring charge of ~$11M-$13M in 1Q25.

Arbutus Biopharma News

Arbutus Biopharma Reports Strong Revenue Growth in Q2 2025

Arbutus Biopharma ( ($ABUS) ) has released its Q2 earnings. Here is a breakdown of the information Arbutus...

22d ago

ABUS

Arbutus Biopharma Appoints New Board Member Amid Strong Q2

The latest announcement is out from Arbutus Biopharma ( ($ABUS) ). On August 4, 2025, Anuj Hasija resigned...

1M ago

ABUS

Arbutus Biopharma reports Q2 EPS 1c vs (11c) last year

Reports Q2 revenue $10.7M, consensus $2.21M. “We delivered a strong quarter, marked by positive quarterly earnings resulting from...

1M ago

ABUS

Arbutus Biopharma’s AB-101 Study: A Potential Game-Changer in Chronic Hepatitis B Treatment

Arbutus Biopharma (($ABUS)) announced an update on their ongoing clinical study. Arbutus Biopharma is conducting a study titled...

2M ago

ABUS

Arbutus Biopharma Ends Partnership with Qilu Pharmaceutical

The latest update is out from Arbutus Biopharma ( ($ABUS) ). On June 20, 2025, Arbutus Biopharma and...

2M ago

ABUS

Arbutus Biopharma reacquires Greater China rights to imdusiran, forms SAB

Arbutus Biopharma (ABUS) announced that it has reacquired China rights to its lead compound, imdusiran, from Qilu Pharmaceutical....

2M ago

ABUS

Arbutus Biopharma Holds Annual Shareholder Meeting

The latest announcement is out from Arbutus Biopharma ( ($ABUS) ). On May 21, 2025, Arbutus Biopharma Corporation...

3M ago

ABUS

Mount Logan Capital Reports Q1 2025 Financial Results

Arbutus Biopharma ( ($ABUS) ) has released its Q1 earnings. Here is a breakdown of the information Arbutus...

4M ago

ABUS

Arbutus Biopharma Achieves Milestones in Hepatitis B Treatment and Expands Leadership

Arbutus Biopharma ( ($ABUS) ) has provided an update. Arbutus Biopharma has announced promising results from its first...

4M ago

ABUS

Arbutus Biopharma reports Q1 EPS (13c), consensus (15c)

Reports Q1 revenue $1.764M, consensus $2.29M. “To date, eight patients have reached functional cure following imdusiran combination therapy....

4M ago

ABUS

Arbutus Biopharma Unveils Promising HBV Treatment Data

Arbutus Biopharma ( ($ABUS) ) has issued an announcement. On May 7, 2025, Arbutus Biopharma presented data at...

4M ago

ABUS

Arbutus Biopharma presents data from two HBV assets

Arbutus Biopharma (ABUS) announced the presentation of five posters, including one late-breaker, highlighting imdusiran, its RNAi therapeutic and...

4M ago

ABUS

Arbutus Biopharma Showcases Promising Hepatitis B Treatments at EASL Congress 2025

Arbutus Biopharma ( ($ABUS) ) has provided an announcement. Arbutus Biopharma announced the acceptance of five abstracts for...

5M ago

ABUS

Arbutus Biopharma Faces Executive Changes Amid Legal Battle

Arbutus Biopharma ( ($ABUS) ) has provided an update. Arbutus Biopharma Corporation announced the termination of two key...

5M ago

ABUS

ABUS FAQ

What was Arbutus Biopharma Corporation’s price range in the past 12 months?

Arbutus Biopharma Corporation lowest stock price was $2.71 and its highest was $4.72 in the past 12 months.

What is Arbutus Biopharma Corporation’s market cap?

Arbutus Biopharma Corporation’s market cap is $732.29M.

When is Arbutus Biopharma Corporation’s upcoming earnings report date?

Arbutus Biopharma Corporation’s upcoming earnings report date is Nov 05, 2025 which is in 61 days.

How were Arbutus Biopharma Corporation’s earnings last quarter?

Arbutus Biopharma Corporation released its earnings results on Aug 06, 2025. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of -$0.048 by $0.058.

Is Arbutus Biopharma Corporation overvalued?

According to Wall Street analysts Arbutus Biopharma Corporation’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Arbutus Biopharma Corporation pay dividends?

Arbutus Biopharma Corporation does not currently pay dividends.

What is Arbutus Biopharma Corporation’s EPS estimate?

Arbutus Biopharma Corporation’s EPS estimate is -0.03.

How many shares outstanding does Arbutus Biopharma Corporation have?

Arbutus Biopharma Corporation has 191,698,700 shares outstanding.

What happened to Arbutus Biopharma Corporation’s price movement after its last earnings report?

Arbutus Biopharma Corporation reported an EPS of $0.01 in its last earnings report, beating expectations of -$0.048. Following the earnings report the stock price went up 1.76%.

Which hedge fund is a major shareholder of Arbutus Biopharma Corporation?

Currently, no hedge funds are holding shares in ABUS

Arbutus Biopharma Stock Smart Score

Neutral

Fundamentals

Return on Equity

-52.82%

Trailing 12-Months

Asset Growth

-35.48%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Arbutus Biopharma Corporation

Arbutus Biopharma Corporation (ABUS) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with hepatitis B virus (HBV) infections and other viral diseases. The company specializes in discovering and commercializing novel drug candidates that target the underlying biology of HBV to improve patient outcomes. Arbutus's core products include a range of antiviral therapies, particularly those that aim to eliminate HBV or significantly reduce viral load in patients.